Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase.
We treated two children who had adenosine deaminase deficiency and severe combined immunodeficiency disease by injecting bovine adenosine deaminase modified by conjugation with polyethylene glycol. The modified enzyme was rapidly absorbed after intramuscular injection and had a half-life in plasma of 48 to 72 hours. Weekly doses of approximately 15 U per kilogram of body weight maintained plasma adenosine deaminase activity at two to three times the level of erythrocyte adenosine deaminase activity in normal subjects. The principal biochemical consequences of adenosine deaminase deficiency were almost completely reversed. In erythrocytes, adenosine nucleotides increased and deoxyadenosine nucleotides decreased to less than 0.5 percent of total adenine nucleotides. The activity of S-adenosylhomocysteine hydrolase, which is inactivated by deoxyadenosine, increased to normal in red cells and nucleated marrow cells. Neither toxic effects nor hypersensitivity reactions were observed. In vitro tests of the cellular immune function of each patient showed marked improvement, along with an increase in circulating T lymphocytes. Clinical improvement was indicated by absence of infection and resumption of weight gain. We conclude that from the standpoints of efficacy, convenience, and safety, polyethylene glycol-modified adenosine deaminase is preferable to red-cell transfusion as a treatment for adenosine deaminase deficiency. Patients with other inherited metabolic diseases in which accumulated metabolites equilibrate with plasma could benefit from treatment with the appropriate polyethylene glycol-modified enzyme.
D000243:Adenosine Deaminase / Q000008:administration & dosage / Q000097:blood / Q000172:deficiency* / Q000627:therapeutic use*; D043383:Adenosylhomocysteinase; D001853:Bone Marrow / Q000201:enzymology; D002648:Child; D002675:Child, Preschool; D004912:Erythrocytes / Q000201:enzymology; D005260:Female; D006801:Humans; D006867:Hydrolases / Q000378:metabolism; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D007273:Injections, Intramuscular; D009700:Nucleoside Deaminases / Q000172:deficiency* / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000494:pharmacology*
D011092:Polyethylene Glycols; D006867:Hydrolases; D043383:Adenosylhomocysteinase; D009700:Nucleoside Deaminases; D000243:Adenosine Deaminase; C051409:pegademase bovine